Oxcarbazepine
Product Images NDC 81033-113

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 81033-113). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Kesin Pharma, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

81033-113-05 Foil Label (81033 113 05)

Label for Oxcarbazepine oral suspension, USP, 300 mg per 5 mL, by Kesin Pharma. The label specifies a 5 mL delivery volume, storage at 59° to 86°F, sugar-free formulation, and instructions for institutional use only. It includes the NDC 81033-113-05, lot number K2404031, and expiration date 10/31/2025.*

FDA Label Image

81033-113-30 Case Pack (81033 113 30)

Label for Oxcarbazepine Oral Suspension, USP delivering 300mg/5mL, packaged by Kesin Pharma. The label specifies 30 unit dose cups of 300mg/5mL each, for institutional use only, with storage instructions from 59°F to 86°F (15°C to 30°C). The expiration date is June 4, 2025.*

FDA Label Image

Structural Formula (Image01)

Chemical structure of Oxcarbazepine showing a dibenzazepine core with an amide side group. The structure includes a bicyclic ring system fused to a ketone and an amide functional group attached to the nitrogen atom in the ring.*

FDA Label Image

Figure 1 (Image02)

Kaplan-Meier survival curve showing exit rates over time (days) from day 2 to day 11 for treatment groups Oxcarbazepine and Placebo, with a Log-Rank test p-value of 0.0001. The graph compares the proportion of participants exiting the trial between the two groups.*

FDA Label Image

Figure 2 (Image03)

A Kaplan-Meier survival curve chart showing seizure rate over time in days from first dose to first seizure, comparing treatment groups Oxcarbazepine and Placebo. The plot includes a Log-Rank Test p-value of 0.046, indicating statistical comparison between groups.*

FDA Label Image

Figure 3 (Image04)

A Kaplan-Meier survival curve chart depicting exit rate over time in days for two treatment groups labeled as HIGH (solid line) and LOW (dashed line). The y-axis shows exit rate from 0 to 1, and the x-axis shows time to exit in days from 0 to 130. A log-rank test p-value of 0.0001 is displayed, indicating statistical comparison of the two curves.*

FDA Label Image

Figure 4 (Image05)

A Kaplan-Meier survival curve chart depicting time to exit over days for two treatment groups labeled 'HIGH' and 'LOW'. The y-axis represents exit rate, and the x-axis shows time to exit in days, with the HIGH group showing a faster increase in exit rate. The chart includes a log-rank test result with a p-value of 0.0001.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.